News

Hypomethylating Agents Plus Venetoclax Regimen Post-Allogeneic Hematopoietic Cell Transplant Relapse for Patients With AML

04/02/2024

Jordan Kadish

The combination of hypomethylating agents plus venetoclax post-allogeneic hematopoietic cell transplant relapse demonstrated efficacy among patients with acute myeloid leukemia, with possibly better outcomes among patients with NPM1 and IDH...

The combination of...

04/02/2024

Oncology

News

Crenolanib Plus Intensive Chemo Demonstrates Efficacy for Patients With Newly Diagnosed FLT3-Mutant AML

04/01/2024

Jordan Kadish

Crenolanib plus intensive chemotherapy demonstrated high rates of deep responses and long-term survival as well as tolerable safety among patients with newly diagnosed FLT3-mutant acute myeloid leukemia.

Crenolanib plus intensive...

04/01/2024

Oncology

News

Hypomethylating Agent, Venetoclax, and Gilteritinib Triplet Regimen for R/R FLT3-Mutated AML

03/13/2024

Jordan Kadish

Combining a hypomethylating agent, venetoclax, and gilteritinib treatment yielded beneficial outcomes and can be used as a bridge to allogeneic stem cell transplantation for patients with R/R FLT3-mutated acute myeloid leukemia.

Combining a hypomethylating...

03/13/2024

Oncology

News

Aspacytarabine Demonstrates Efficacy and Safety Benefits for Patients With AML Unfit for Intensive Chemotherapy

02/23/2024

Jordan Kadish

Aspacytarabine demonstrated efficacy and safety among patients with acute myeloid leukemia who were older or unfit for intensive chemotherapy, according to a phase 2 study.

Aspacytarabine demonstrated...

02/23/2024

Oncology

News

Fractionated Gemtuzumab Ozogamicin Results in Improved Survival and MRD Reduction Among Older Patients With AML

02/08/2024

Jordan Kadish

A fractionated schedule of gemtuzumab ozogamicin resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab ozogamicin.

A fractionated schedule of...

02/08/2024

Oncology

News

Vibecotamab Treatment at Dose-Optimized Schedule Shows Promise Among Patients With R/R AML

01/18/2024

Jordan Kadish

Vibecotamab administered at a dose-optimized schedule showed promise and demonstrated an acceptable safety profile among patients with relapsed/refractory acute myeloid leukemia.

Vibecotamab administered at a...

01/18/2024

Oncology

Conference Coverage

Hypomethylating Agent Monotherapy Compared With Hypomethylating Agent Plus Venetoclax Regimen Among Patients With Untreated TP53-Mutated AML

01/03/2024

Featuring Talha Badar, MD

At the 65th ASH Annual Meeting, Talha Badar, MD, discusses a retrospective study on the efficacy of venetoclax combined with hypomethylating agent (HMA) therapy vs HMA monotherapy for patients with TP53-mutated acute myeloid leukemia.

At the 65th ASH Annual Meeting,...

01/03/2024

Oncology

Conference Coverage

Hypomethylating Agent Monotherapy Compared With Hypomethylating Agent Plus Venetoclax Regimen Among Patients With Untreated TP53-Mutated AML

01/03/2024

Featuring Talha Badar, MD

At the 65th ASH Annual Meeting,...

01/03/2024

Oncology

Conference Coverage

Long-Term Survival Rates and Discontinuation of Venetoclax/Azacitidine for Responding Patients With AML

12/15/2023

Featuring Sylvain Garciaz, MD

At the 65th ASH Annual Meeting, Sylvain Garciaz, MD, shared insights on the potential benefit of stopping venetoclax and/or azacytidine treatment for responding patients with acute myeloid leukemia.

At the 65th ASH Annual Meeting,...

12/15/2023

Oncology

Conference Coverage

Long-Term Survival Rates and Discontinuation of Venetoclax/Azacitidine for Responding Patients With AML

12/15/2023

Featuring Sylvain Garciaz, MD

At the 65th ASH Annual Meeting, Sylvain Garciaz, MD, shared insights on the potential benefit of stopping venetoclax and/or azacytidine treatment for responding patients with acute myeloid leukemia.

At the 65th ASH Annual Meeting,...

12/15/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology